Nat. Rev. Rheumatol. doi: /nrrheum

Slides:

Advertisements

Similar presentations

V  -J . T Cell Maturation in the Thymus Positive selection: permits the survival of only those T cells whose TCRs are capable of recognizing self-MHC.

Advertisements

Figure 1 CTLA-4 and PD-1–PD-L1 immune checkpoints

Transplant: immunology and treatment of rejection

Nat. Rev. Rheumatol. doi: /nrrheum

of different experimental arthritis models

Immunological Tolerance

Figure 5 Involvement of B cells in SLE

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 Induction of immune tolerance

Figure 1 Immunomodulatory monoclonal antibodies and armoured chimeric antigen receptor (CAR) T cells overcome immune suppression Figure 1 | Immunomodulatory.

Figure 4 Simplified T cell and antigen presenting

Scratching the Surface of Immunotherapeutic Targets in Neuroblastoma

Figure 1 Chimeric antigen receptor (CAR) structures

Figure 2 Peptide vaccination using TAA-derived long peptides

Antibody-modified T cells: CARs take the front seat for hematologic malignancies by Marcela V. Maus, Stephan A. Grupp, David L. Porter, and Carl H. June.

Immunology Cell Volume 100, Issue 1, Pages (January 2000)

Figure 5 Defects in the JAK–STAT signalling pathway

Nat. Rev. Rheumatol. doi: /nrrheum

Engineering regulatory T cells against factor VIII inhibitors

Figure 2 Targeted versus untargeted metabolomics approaches

Figure 1 Metabolic profiling as a tool for studying rheumatic diseases

Figure 3 Transcriptome studies performed in the target

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 7 Defects in apoptosis

Autoreactive CD8 T Cells in Organ-Specific Autoimmunity

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 1 Location of HLA variants known to be associated

Nat. Rev. Nephrol. doi: /nrneph

Figure 1 CAR-T-cell design

Figure 3 TNFSF activities enhancing immune cell activation

Figure 2 Co-stimulatory receptors as immunomodulatory targets

Figure 4 Combination immunotherapeutic approaches with imatinib

Figure 3 Defects in the T cell receptor signalling pathway

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum

Scratching the Surface of Immunotherapeutic Targets in Neuroblastoma

Figure 4 Approaches to targeting inhibitory immune receptors

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 3 Differentiation and functional control of T-cell subsets

Figure 3 Multi-hit model for autoimmune diseases

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum

Molecular Therapy - Methods & Clinical Development

Like Angler Fish, CAARs Lure Their Prey

Figure 1 The current model of the pathogenesis of SLE

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Endocrinol. doi: /nrendo

The Other Face of Chimeric Antigen Receptors

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 2 Biologics that target CD4+ T helper (TH)-cell subsets

Figure 1 Mechanisms of action of immunotherapy modalities

Figure 3 Nuclear-penetrating autoantibodies and synthetic lethality

Immunology Dr. Refif S. Al-Shawk

Immunological Tolerance

Figure 2 Cellular contributions to the development of SLE

Figure 1 Extrinsic and intrinsic pathways of apoptosis

Figure 1 The role of macrophages in RA

Figure 2 The main effects of adipokines on bone remodelling in osteoarthritis Figure 2 | The main effects of adipokines on bone remodelling in osteoarthritis.

SLE: the many players involved in systemic autoimmunity and tissue destruction. SLE: the many players involved in systemic autoimmunity and tissue destruction.

Releasing the Brakes on Cancer Immunotherapy

Human cancer immunotherapy strategies targeting B7-H3 A, blockade of B7-H3 with blocking mAbs neutralizes inhibitory signaling in its unidentified receptor(s)

Figure 2 Involvement of plasmacytoid dendritic cells

Presentation transcript:

Nat. Rev. Rheumatol. doi:10.1038/nrrheum.2017.107 Figure 3 Strategies for neutralizing or re‑programming autoreactive T cells Figure 3 | Strategies for neutralizing or re‑programming autoreactive T cells. a | Autoreactive T cells can be detected with MHC–peptide tetramers coupled to a fluorescent dye and eliminated with MHC–peptide tetramers coupled to a toxin. Ethylene carbodiimide (ECDI)-fixed apoptotic cells coupled with antigen (antigen-coupled carrier cells) can be used to induce tolerance of autoreactive T cells either directly by presenting antigen to T cells to induce anergy, or indirectly by being taken up by host antigen presenting cells (APCs), which subsequently present antigens to T cells to induce regulatory T (Treg) cell differentiation and expansion. Peptide-coated nanoparticles containing rapamycin or encapsulated peptide-containing nanoparticles can also be taken up by host APCs to induce Treg cell differentiation. Finally, tetramerized MHC–peptide complexes and peptide-coated nanoparticles can directly induce Treg cell differentiation. b | T cells can be engineered to specifically target autoimmunity. Chimeric antigen receptors (CARs), consisting of an autoantibody-derived antigen-binding domain and a T cell signalling domain (that is, the CD137 and the CD3ξ signalling domain of the T cell receptor), can be introduced to T cells, in addition to the murine Foxp3 gene, to create autoantigen-specific Treg cells (CAR Treg cells). Introduction of the chimeric autoantibody receptor (CAAR), consisting of an autoantigen epitope recognized by autoreactive B cell receptors (BCRs) and CD137 + CD3ξ signalling domain of the T cell receptor, can enable a T cell to specifically kill autoantigen-specific B‑cells . Pozsgay, J. et al. (2017) Antigen-specific immunotherapies in rheumatic diseases Nat. Rev. Rheumatol. doi:10.1038/nrrheum.2017.107